Prostatype Genomics presents Quarterly- & Year End Report
Prostatype Genomics AB has today published its quarterly report for the fourth quarter comprising the period from 1 October 2022 to 31 December 2022, and the year end report for the financial year 2022. The report is available on the company website.Quarter 4 (1 October – 31 December 2022) summarized · Net sales amounted to 304 (0) TSEK. · EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -7 673 (-5 712) TSEK. · Cash flow from current operations in the quarter amounted -7 850 (-5 381) TSEK. · Total cash flow for the period amounted to – 7 950